Population genetic analysis of the Plasmodium falciparum circumsporozoite protein in two distinct ecological regions in Ghana. by Amegashie, Elikplim A et al.
Amegashie et al. Malar J          (2020) 19:437  
https://doi.org/10.1186/s12936-020-03510-3
RESEARCH
Population genetic analysis 
of the Plasmodium falciparum circumsporozoite 
protein in two distinct ecological regions 
in Ghana
Elikplim A. Amegashie1, Lucas Amenga‑Etego2†, Courage Adobor3, Peter Ogoti1, Kevin Mbogo1, 
Alfred Amambua‑Ngwa4† and Anita Ghansah3*† 
Abstract 
Background: Extensive genetic diversity in the Plasmodium falciparum circumsporozoite protein (PfCSP) is a major 
contributing factor to the moderate efficacy of the RTS,S/AS01 vaccine. The transmission intensity and rates of recom‑
bination within and between populations influence the extent of its genetic diversity. Understanding the extent and 
dynamics of PfCSP genetic diversity in different transmission settings will help to interpret the results of current RTS,S 
efficacy and Phase IV implementation trials conducted within and between populations in malaria‑endemic areas 
such as Ghana.
Methods: Pfcsp sequences were retrieved from the Illumina‑generated paired‑end short‑read sequences of 101 and 
131 malaria samples from children aged 6–59 months presenting with clinical malaria at health facilities in Cape Coast 
(in the coastal belt) and Navrongo (Guinea savannah region), respectively, in Ghana. The sequences were mapped 
onto the 3D7 reference strain genome to yield high‑quality genome‑wide coding sequence data. Following data fil‑
tering and quality checks to remove missing data, 220 sequences were retained and analysed for the allele frequency 
spectrum, genetic diversity both within the host and between populations and signatures of selection. Population 
genetics tools were used to determine the extent and dynamics of Pfcsp diversity in P. falciparum from the two geo‑
graphically distinct locations in Ghana.
Results: Pfcsp showed extensive diversity at the two sites, with the higher transmission site, Navrongo, exhibiting 
higher within‑host and population‑level diversity. The vaccine strain C‑terminal epitope of Pfcsp was found in only 
5.9% and 45.7% of the Navrongo and Cape Coast sequences, respectively. Between 1 and 6 amino acid variations 
were observed in the TH2R and TH3R epitope regions of PfCSP. Tajima’s D was negatively skewed, especially for the 
population from Cape Coast, given the expected historical population expansion. In contrast, a positive Tajima’s D 
was observed for the Navrongo P. falciparum population, consistent with balancing selection acting on the immuno‑
dominant TH2R and TH3R vaccine epitopes.
© The Author(s) 2020. This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, 
adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and 
the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material 
in this article are included in the article’s Creative Commons licence, unless indicated otherwise in a credit line to the material. If material 
is not included in the article’s Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the 
permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creat iveco 
mmons .org/licen ses/by/4.0/. The Creative Commons Public Domain Dedication waiver (http://creat iveco mmons .org/publi cdoma in/




†Lucas Amenga‑Etego, Alfred Amambua‑Ngwa and Anita Ghansah 
equally contributed to this work
3 Parasitology Department, Noguchi Memorial Institute of Medical 
Research, University of Ghana, , Legon, Ghana
Full list of author information is available at the end of the article
Page 2 of 14Amegashie et al. Malar J          (2020) 19:437 
Background
Stagnation in the decline of malaria over the last 5 years 
indicates that global malaria elimination targets may not 
be achieved without the addition of a broadly effective 
vaccine to complement the panel of available malaria 
control tools [1]. However, it has taken over 15 years to 
finally license a moderately efficacious malaria vaccine 
for implementation due to extreme levels of antigenic 
diversity of most vaccine candidates, which reduces their 
efficacy across a broad range of evolving natural parasite 
populations.
Efficacy data from a Phase III clinical trial conducted 
across 11 sites in 7 African countries in children (aged 
5 to 17 months) and infants (aged 6–12 weeks) revealed 
that the vaccine conferred moderate protective efficacy 
against clinical disease and severe malaria which waned 
over time [2]. The vaccine conferred only 36.3% protec-
tion against clinical malaria and 32.2% against severe 
malaria in children aged 5–17  months who received 3 
primary doses of RTS,S with a booster in the 20th month 
[2]. The European Medicines Agency gave a favourable 
scientific opinion in 2015, indicating how the benefits of 
protective immunity outweigh the risk and the poten-
tially high impact this moderate efficacy could have, given 
the huge disease burden [3]. Subsequently, Ghana, Kenya 
and Malawi were selected for pilot Phase IV implementa-
tion trials that are currently underway, carried out by the 
Malaria Vaccine Implementation Programme (MVIP) led 
by the World Health Organization (WHO) [4].
The RTS,S vaccine is a malaria subunit vaccine that 
is formulated from a fragment of the circumsporozoite 
protein (CSP) of Plasmodium falciparum 3D7 labora-
tory strain fused with the Hepatitis B surface antigen 
and the AS01 adjuvant [5]. For cell-mediated immu-
nity, RTS,S includes a fragment of the central NANP-
NVDP repeat polymorphic B-cell epitope region and 
a highly polymorphic C-terminal non-repeat epitope 
region of PfCSP, which covers  CD4+ and  CD8+ T-cell 
epitopes denoted as TH2R and TH3R, respectively 
[6]. Several studies have reported high levels of poly-
morphism in the T-cell epitopes within the C-terminal 
region of PfCSP in natural parasite populations [7–10]. 
Although there are variations in the immunodominant 
central repeat region (CRR), it was hoped that antibod-
ies targeting a single dominant epitope based on the 
tetrapeptide repeat NANP would provide strain-sur-
passing immunity. This hope was strengthened by the 
findings of a molecular epidemiology study in African 
children that showed no evidence of naturally acquired 
strain-specific immunity to different variants of CSP 
obtained using the 454 sequencing platform [8]. In 
addition, initial ancillary studies on Phase II clinical 
trials conducted at three sites, including The Gambia, 
Kenya and Mozambique, revealed that the immune pro-
tection conferred by the RTS,S/AS02 vaccine was not 
strain-specific even after vaccination [11–14]. However, 
these studies were based on only a few hundred isolates 
and were not statistically powered to detect moderate 
effects, such as the strain-specific immune response of 
the vaccine.
Subsequently, an ancillary next-generation deep 
sequencing analysis of Phase III trial samples in 2015 
showed that the vaccine indeed conferred partial pro-
tection against clinical malaria for strain-specific 
vaccine alleles (50.3%) and poor protection against 
mismatched strains (33.3%) [15]. Additionally, recent 
studies of the population structure of Pfcsp suggest 
that geographically variable levels of diversity and geo-
graphic restriction of specific subgroups may have an 
impact on the efficacy of Pfcsp-based malaria vaccines 
in specific geographic regions [7, 16]. In particular, 
extreme global genetic diversity of Pfcsp strains has 
been reported, with the 3D7 vaccine strain being found 
only in approximately 5.0% and 0.2% in some African 
and Asian countries, respectively [16].
The need to explore the extent of genetic diversity 
and the natural dynamics of malaria vaccine antigens 
in endemic areas where vaccines will be deployed is a 
point of focus due to the polymorphic nature of P. fal-
ciparum antigens [15–17]. Furthermore, evolutionary 
factors such as selection operating on parasites differ 
locally owing to varying transmission patterns, ecol-
ogy and degrees of acquired immunity in humans [18]. 
Therefore, further characterization of the genetic diver-
sity of immune epitopes of vaccine antigens is impor-
tant, especially in regions such as Ghana, where the 
vaccine is undergoing the Phase IV implementation 
trial. This should provide a broader assessment of the 
extent to which the local natural diversity could impact 
efficacy and wider implementation.
Conclusion: The low frequencies of the Pfcsp vaccine haplotype in the analysed populations indicate a need for 
additional molecular and immuno‑epidemiological studies with broader temporal and geographic sampling in 
endemic populations targeted for RTS,S application. These results have implications for the efficacy of the vaccine in 
Ghana and will inform the choice of alleles to be included in future multivalent or chimeric vaccines.
Keywords: Plasmodium falciparum circumsporozoite protein, Genetic diversity, Selection, Within‑host diversity
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Malaria transmission in Ghana is generally perennial 
but with marked seasonal effects that vary with the local 
ecology and overall transmission intensity [19]. For con-
trol purposes, malaria transmission across Ghana has 
been eco-epidemiologically classified into three main 
zones: a forest ecology zone, with perennial but high 
transmission during the rainy season (May–August and 
October–November); a northern/Guinea savannah zone, 
showing seasonal and intense malaria transmission dur-
ing the rainy season (June-October) but also periods 
of very low transmission during the dry season; and a 
coastal savannah zone, with low to moderate perennial 
transmission and a marked seasonal effect during the 
rainy season [20].
The implementation trial of RTS,S vaccine is being con-
ducted in three regions, namely, the Brong-Ahafo and 
Volta regions in the forest ecology zone and the Cen-
tral region in the coastal belt, with varying transmission 
levels. Understanding the extent and drivers of diversity 
in these regions could also have a profound impact on 
improving the design of future circumsporozoite protein-
based vaccines. Using paired-end short-read sequences 
of the Pfcsp in parasite populations from two geographi-
cally distinct sites in Ghana, within-host diversity (com-
plexity of infection) and the extent of population-specific 
haplotype diversity of the c-terminal region of Pfcsp 
encompassing the TH2R and TH3R epitopes were inves-
tigated. Information on diversity most relevant to vaccine 
escape and cross-protection are provided. PfCSP amino 
acid diversity and conservation were further explored. 
In addition, evidence of selection on Pfcsp that could 




The study was conducted at two sites, the Cape Coast 
Metropolitan area, where Cape Coast is the main town-
ship, and the Kassena-Nankana districts (KNDs), where 
Navrongo is the main township (Fig.  1). Cape Coast is 
located in the Southern coastal savannah region, show-
ing low to moderate perennial malaria transmission with 
a marked seasonal effect during the rainy season (May–
August and October–November). The estimated annual 
entomological inoculation rate (EIR) is fewer than 50 
infective bites per person per year [20]. The KNDs are 
located in the Upper East Region of Ghana with a Guinea 
savannah vegetation. Malaria is perennial in the KNDs, 
with high seasonal malaria transmission during the rainy 
season (June to October) and minimal transmission dur-
ing the rest of the year, which are relatively dry months. 
The estimated annual EIR for the KNDs is up to 157 
infective bites per person per year [21].
In Cape Coast, P. falciparum parasites were isolated 
from 101 children (aged 6–59 months) living within the 
municipality and presenting with clinical malaria at the 
Fig. 1 Location of Navrongo within the Kassena‑Nankana Districts and Cape Coast within the Cape Coast Metropolis. The distance between Cape 
Coast and Navrongo is approximately 784.8 km (generated by QGIS software)
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Cape Coast District hospital. Samples were collected 
during the major rainy season (May–August) in 2013. In 
Navrongo, P. falciparum parasites were isolated from 131 
children aged between 12–59  months who lived in the 
KNDs and presented with P. falciparum clinical malaria 
at health facilities in the KNDs in the years 2010 (Janu-
ary to October), 2011 (January to February) and 2013 
(August to October) during both the dry and wet sea-
sons. At both study sites, children presenting with fever, 
i.e., an axillary temperature ≥ 37.5° or a history of fever 
during the previous 24  h, were screened with malaria 
rapid diagnostic test (RDT). Blood smears were prepared 
for RDT-positive individuals and P. falciparum asexual 
parasites were identified by microscopy. Venous blood 
(2–5 mL) from P. falciparum-infected patients who gave 
consent was collected and archived.
Genomic DNA extraction and sequencing
Genomic DNA was extracted using the QiaAmp DNA 
prep kit (Qiagen, Valencia, CA) following the manufac-
turer’s protocol, and the confirmation of P. falciparum-
positive samples was performed by amplification using 
nested PCR with specific primers [22] (see Additional 
file  1). The Genomic DNA was submitted to the Well-
come Trust Sanger Institute Hinxton, UK, for whole-
genome sequencing using the Illumina HiSeq platform 
as part of the MalariaGEN community project. Illumina 
sequencing libraries (200  bp insert) were aligned to the 
reference P. falciparum 3D7 genome, after which vari-
ant calling was conducted via the customized GATK 
pipeline. Each sample was genotyped for 797,000 poly-
morphic biallelic coding SNPs across the genome ensur-
ing a minimum of 5 × paired-end coverage across each 
variant per sample. The dominant allele was retained 
in the genotype file at loci with mixed reads (reference/
non-reference). The genotypes were assigned denoting 
the reference and non-reference nucleotides as 0 and 1, 
respectively. Polymorphic sites with low call rates and 
those in hypervariable, telomeric and repetitive sequence 
regions were excluded.
Sequence acquisition and pre‑processing
Genome sequences from Navrongo and Cape Coast were 
mined from the MalariaGEN Plasmodium falciparum 
Community (Pf3k) Project release 5.1 Database [23] in 
variant call format (VCF). Genetic variants on chromo-
some 3 were retrieved from both Navrongo and Cape 
Coast. In the VCF file for Cape Coast, all genotypes at 
each SNP position were monoallelic (monoclonal); bial-
lelic genotypes were modelled using a custom Python 
script. This process was based on the approach of the 
MalariaGEN Pf3k Project, where loci with mixed allele 
calls were modelled using the read and allelic depth 
[24]. Briefly, to account for PCR errors, the genotypes of 
SNPs with a read depth < 5 were not determined. At SNP 
positions with a read depth ≥ 5, the samples were geno-
typed as heterozygous if the allelic depth of both alleles 
was ≥ 2. The remaining alleles were genotyped as either 
the homozygote reference allele or homozygote alterna-
tive/derived allele.
Data for both populations were filtered to obtain only 
biallelic SNPs using Bcftools v1.9 and quality checked 
as follows: only SNPs that passed all VCF filters were 
retained. Isolates with > 10% missing SNPs were excluded, 
followed by the removal of SNPs with > 5% missing data 
using PLINK v1.9 [25]. Furthermore, heterozygosity was 
calculated, and 8 isolates with outlier heterozygosity 
within the Cape Coast population were excluded. No 
outlier heterozygosity was observed in Navrongo. SNPs 
with a minor allele frequency (MAF) < 1% were removed. 
The remaining missing SNPs were imputed and phased 
using Beagle v5.1 [26]. After quality control, in the Cape 
Coast dataset, 2504 SNPs out of 26,156 on chromosome 
3 and 92 out of 101 samples remained. However, the 
Navrongo dataset retained 1954 out of 43,199 SNPs on 
chromosome 3 and 128 out of 131 samples. Pfcsp was 
then extracted from chromosome 3 (position: 221,323–
222,516) and 13 and 22 SNPs at the selected CSP loci 
were retained for Cape Coast and Navrongo, respectively.
Population genetics analysis
Minor allele frequency distribution
Prior to the removal of rare alleles (MAF ≤ 0.01), the 
minor allele frequency distribution for all putative SNPs 
(n = 90) within Pfcsp for both Cape Coast (n = 35 SNPs) 
and Navrongo (n = 55 SNPs) P. falciparum isolates was 
determined using Plink1.9. The MAF is the frequency 
with which the second most common allele occurs at a 
given SNP position in a population.
Within‑host parasite diversity estimation and statistical 
analysis
The genetic diversity within the individuals was assessed 
by estimating Wright’s inbreeding co-efficient (Fws). For 
this analysis, the within-host diversity of Pfcsp, which 
refers to the number of different Pfcsp strains con-
tained within an individual infection, was estimated. The 
retained variants (13 and 22 SNPs) from the 92 Cape 
Coast isolates and 128 Navrongo isolates were used for 
this analysis.
The Fws metric estimates the heterozygosity of para-
sites  (HW) within an individual relative to the heterozy-
gosity within a parasite population  (HS) using the read 
count of alleles. Fws metric calculation for each sample 
was performed using the following equation:
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where  HW refers to the allele frequency of each unique 
allele found at specific loci of the parasite sequences 
within the individual, and  HS refers to the corresponding 
allele frequencies of those unique alleles within the popu-
lation [27, 28]. Fws ranges from 0 to 1; a low Fws value 
indicates low inbreeding rates within the parasite popu-
lation and thus high within-host diversity relative to the 
population. An Fws threshold ≥ 0.95 indicates samples 
with clonal (single strain) infections, while samples with 
an Fws < 0.95 are considered highly likely to come from 
mixed strain infections, indicating within-host diversity. 
Fws was calculated using an R package, moimix [29]. 
Samples with clonal infections were used for selection 
analysis. The Pearson chi-squared test was used to meas-
ure the statistical significance of any differences observed 
in the within-host diversity estimates between the popu-
lation pair. The test was performed using R software with 
P values < 0.05 considered statistically significant.
Genetic diversity within parasite populations
The haplotype diversity (the number of two random 
strains within the population having different haplotypes) 
of Pfcsp in each population was determined by exploring 
the variants in the C-terminal region of the gene (909–
1140  bp). One hundred and eighty four Pfcsp FASTA 
DNA sequences were re-constructed with the retained 
variants (13 SNPs) from the 92 Cape Coast isolates and 
256 DNA sequences (22 SNPs) from the 128 Navrongo 
isolates using an in-house Python script.
The following metrics were then used to assess the 
diversity of the Pfcsp C-terminus within each parasite 
population using DnaSP software (version 6.10.01) [30]: 
number of sequences (n), number of haplotypes (h), seg-
regating sites (S), average number of pairwise nucleotide 
differences (K), nucleotide diversity (π) and haplotype 
diversity (Hd) [31, 32].
To assess the genealogical relationships between Pfcsp 
C-terminal haplotypes found in Navrongo and Cape 
Coast, a network based on the method described by 
Templeton, Crandall, and Sing (TCS) [33, 34] was con-
structed using PopArt [35]. The haplotypes were denoted 
as 3D7, Hap 2 up to Hap 66 in the network.
In addition, amino acid haplotypes within each popu-
lation were explored by translating all 440 Pfcsp DNA 
sequences (Cape Coast (184) and Navrongo (256)) into 
amino acid sequences and comparing them to the 3D7 
reference strain (0304600.1, PlasmoDB [36]) using in-
house Python scripts. The frequency of TH2R 311–327 
amino acid (PSDKHIKEYLNKIQNSL) and TH3R 352–
363 amino acid (NKPKDELDYAND) haplotypes in each 
Fws = 1− HW/HS
parasite population were determined also using a cus-
tomized Python script and plotted.
Population differentiation and structure analysis
The Wright Fixation index (Fst) and principal compo-
nent analysis (PCA) were used for population differentia-
tion and structure analyses. To reduce bias in Fst analysis 
and PCA, SNPs (from the 2504 Cape Coast chromosome 
3 retained SNPs and the 1954 Navrongo retained SNPs) 
with pairwise linkage disequilibrium (LD) values  r2 > 0.5 
within a window of 100  bp in the entire chromosome 
3 dataset were pruned out using a step size of 10. The 
remaining SNPs set at chromosome 3 shared between 
the populations after pruning was 516, of which 10 were 
Pfcsp SNPs.
The Pfcsp SNPs were then used to estimate Fst and 
population structure. The Weir and Cockerham Fst per 
SNP between Cape Coast and Navrongo parasite isolates 
was calculated using Vcftools v0.1.5 [37] and population 
structure by PCA was performed using smartpca (Cam-
bridge, MA, USA) in EIGENSOFT package v6.1.3 [38]. 
Principal components were computed with the number 
of outlier removal iterations set at 10 while maintaining 
other parameters. In all, 10 PCs were computed with 5 
and 9 outlier samples removed from the 92 and 128 iso-
lates from Cape Coast and Navrongo, respectively. Thus, 
there remained 83 samples in the Cape Coast population 
and 123 samples in the Navrongo population after outlier 
samples were removed.
Signatures of selection
To test for SNP neutrality, the Tajima’s D statistical test 
[39] was performed in sliding windows with a size of 
100 bp and a step size of 10 with Pfcsp monoclonal sam-
ples from each population using Vcftools v0.1.5. Tajima’s 
D test compares the average pairwise differences (pi) and 
the total number of segregating sites (S). Negative values 
indicate directional or purifying selection, while positive 
values indicate balancing the selection.
To detect loci likely to be under recent positive selec-
tion in the Cape Coast and Navrongo monoclonal 
chromosome 3 isolates, the standardized integrated hap-
lotype score (|iHS|) was calculated for each SNP with an 
MAF > 0.05 on chromosome 3 (358 out of the 2504 and 
608 out of the 1954 remaining SNPs from Cape Coast 
and Navrongo, respectively) [40]. Again, for the pur-
pose of this analysis, the Fws metric was used to estimate 
these monoclonal chromosome 3 isolates in the retained 
variants within the chromosome 3 region (2504 in Cape 
Coast and 1954 SNPs in Navrongo).
|iHS| measures the amount of extended haplotype 
homozygosity (EHH) at a given SNP in the ancestral 
allele relative to the derived allele [40]. The reference 
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and alternate alleles were characterized as ancestral and 
derived alleles, respectively. This was performed in R 
using the rehh package v2.0.4 [41]. Genomic regions 
under positive selection were identified as those with 
multiple SNPs showing |iHS| values > 3 and provided the 
focal SNPs for extended haplotype homozygosity (EHH) 
analysis. EHH for both the reference and alternate alleles 
was calculated, and bifurcation plots were generated to 
visualize the decay of EHH at increasing distances from 
the focal SNP loci [42] using rehh package v2.0.4 in R.
Results
Minor allele frequency distribution of Pfcsp
A total of 90 SNPs within Pfcsp were analysed for the 
minor allele frequency (MAF). The P. falciparum popula-
tion from Navrongo showed more variability in Pfcsp (55 
SNPs) than the Cape Coast population (35 SNPs) (Fig. 2). 
The allele frequency distribution of all putative SNPs 
within the Pfcsp loci ranged from 0.001–0.45 in Nav-
rongo and 0.001–0.40 in Cape Coast (Fig. 2). As expected 
for natural P. falciparum populations in Africa (high 
transmission settings), the allele frequency spectrum was 
dominated by very-low-frequency alleles (MAF ≤ 0.05) 
in both populations. Rare alleles (MAF ≤ 0.01) were 
observed at frequencies of 62.9% (22/35) and 61.8% 
(34/55) in Cape Coast and Navrongo, respectively. A total 
of 20% (7/35) and 10.9% (6/55) low-frequency variants 
[MAF range = (0.01–0.05)] were observed in Cape Coast 
and Navrongo, respectively. However, the remaining 
alleles showed a moderate to high MAF in both popula-
tions, implying some underlying evolutionary events.
Within‑host genetic diversity of Pfcsp
To assess the within-host diversity of Pfcsp in the popu-
lation, the inbreeding coefficient (FWS) was investigated. 
Isolates with Fws values ≥ 0.95 were considered single 
strain (or monoclonal) infections, while Fws < 0.95 indi-
cated diverse multigene infections. In Cape Coast, 71.7% 
of Pfcsp isolates (66/92) came from single-strain infec-
tions with high inbreeding potential, while 28.3% (26/92) 
came from highly diverse multistrain infections with 
high potential for outcrossing (Fig. 3). For P. falciparum 
Fig. 2 A histogram showing the minor allele frequency distribution of a total of 90 SNPs located within Pfcsp loci in samples from both Cape Coast 
(n = 35 SNPs) and Navrongo (n = 55 SNPs). The vertical axis represents the number of SNPs in each category of allele frequency, and the horizontal 
axis shows the SNPs set in the respective MAFs range. There were no alleles found within the [0.25–0.30] and [0.30–0.35] MAF ranges in both 
populations
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infections from Navrongo, 50.8% (65/128) were mono-
clonal Pfcsp isolates, and 49.2% (63/128) harboured mul-
tiple Pfcsp strains (Fig.  3). The Navrongo Pfcsp isolates 
exhibited significantly higher within-host diversity than 
those from Cape Coast (χ2 = 15.382, p = 0.00009).
Genetic diversity of Pfcsp C‑terminal haplotypes
To assess the extent of genetic diversity and similarity 
within and between the two populations, the diversity in 
the C-terminal region of Pfcsp (231 bp) was investigated 
from a total of 440 DNA sequences from Cape Coast 
(n = 184) and Navrongo (n = 256) (Table 1) and summa-
rized in a Templeton, Crandall, and Sing (TCS) network 
(Fig. 4).
In total, 66 haplotypes were observed among the 
440 Pfcsp sequences obtained from both populations 
(Fig.  4). Among these haplotypes, 15 and 53 were 
found in the Cape Coast and Navrongo populations, 
Fig. 3 Within‑host diversity. Bar plot showing the percentages of monoclonal and polyclonal samples in Navrongo and Cape Coast populations. 
Monoclonal samples are highlighted in green, and polyclonal samples are highlighted in purple
Table 1 Diversity indices of the Pfcsp C-terminal region of samples included in the network analysis
n  number of sequences, h number of unique haplotypes, S number of segregating sites, K average number of pairwise nucleotide differences, π nucleotide diversity, 
Hd haplotype diversity
Population n Calculated indices
h S K π ± S.D Hd± S.D
Cape Coast 184 15 8 1.15 0.005 ± 0.0004 0.718  ±  0.026
Navrongo 256 53 16 3.76 0.016 ±  0.0007 0.925  ±  0.009
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respectively. The RTS,S vaccine haplotype (Pf3D7-type) 
and 1 nonvaccine haplotype (denoted as “Hap 10”) were 
found in both populations (Fig. 4). The Pf3D7-type hap-
lotype represented only 5.9% (n = 15/256) of haplotypes 
in Navrongo but 45.7% (n = 84/184) in Cape Coast 
(see Additional file  2). Only a single sample exhibited 
Hap 10 from Navrongo (0.4%), but this haplotype rep-
resented 6.0% of the total haplotypes in Cape Coast 
(11/184 isolates) (Additional file  2). While the Pf3D7-
type haplotype was the most prevalent Pfcsp C-termi-
nal haplotype (45.7%) in isolates from Cape Coast, the 
most frequent haplotype in the Navrongo isolates was 
Fig. 4 Templeton, Crandall, and Sing (TCS) network providing a summary of the diversity of Pfcsp haplotypes in the C‑terminal region obtained 
from 440 DNA sequences in both Cape Coast (n = 184) and Navrongo (n = 256). Circles represent each Pfcsp C‑terminal haplotype, and circles are 
scaled according to the frequency with which the haplotype was observed. Each haplotype is denoted as “Hap” with the vaccine strain 3D7 (3D7 
0,304,600.1, PlasmoDB [38]) denoted as “3D7”. Haplotypes obtained from the Navrongo sequences are colour‑coded blue, and haplotypes obtained 
from Cape Coast coded red
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“Hap 16”, representing 20.3% (52/256) of the haplotypes 
detected (Additional file 2).
According to the analysed genetic diversity indices, the 
Pfcsp C-termini of the Navrongo isolates were generally 
more diverse than those from Cape Coast (Table  1). In 
summary, more nucleotide polymorphisms (K = 3.761) 
and segregating sites (S = 16) were observed in Navrongo 
than in Cape Coast (K = 1.148, S = 8). Consequently, 
Pfcsp nucleotide diversity ( π) was higher in the Nav-
rongo isolates ( π = 0.016± 0.0007) than in the isolates 
from Cape Coast ( π = 0.005 ± 0.0004). Haplotype diver-
sity was also higher in Navrongo (Hd = 0.925 ± 0.009) 
in comparison with Cape Coast (0.718 ± 0.026) parasite 
isolates.
TH2R and TH3R amino acid haplotype diversity
The TH2R and TH3R sites were more polymorphic 
in both populations than the remaining amino acid 
sequence in the C-terminal region of PfCSP. In general, 
non-synonymous mutations predominated in all the 
isolates in both TH2R and TH3R epitope regions, with 
implications for cross-protection. Among the 92 (184 
amino acid haplotypes) and 128 (256 amino acid hap-
lotypes) isolates from Cape Coast and Navrongo, there 
were 8 and 27 nonvaccine TH2R haplotypes, respec-
tively (see Additional file  3). There were also 2 and 10 
nonvaccine TH3R haplotypes in Cape Coast and Nav-
rongo, respectively, with 1 nonvaccine haplotype (NKPK-
DELNYAND) being shared between the two populations 
(Additional file  3). The frequencies of the Pf3D7-type 
TH2R vaccine haplotype (PSDKHIKEYLNKIQNSL) were 
56.5% and 7.4% in Cape Coast and Navrongo, respectively 
(Fig. 5a), while the frequencies were 79.3% and 18.4% for 
the Pf3D7-type TH3R vaccine haplotype (NKPKDELDY-
AND) (Fig.  5b) in the Cape Coast and Navrongo iso-
lates, respectively. The amino acid differences observed 
between Pf3D7 reference (3D7 0304600.1, PlasmoDB) 
and the Ghanaian isolates ranged from 1 to 6 in both 
epitope regions (see Additional file 3).
Population differentiation and structure of Pfcsp
The overall Weir and Cockerham’s Fst between the 
Cape Coast and Navrongo Pfcsp populations was < 0.05 
(Fig.  6a), which indicates minimal population differen-
tiation due to genetic structure and suggests gene flow 
between the populations, despite the geographic distance 
between the sites. This also confirms the lack of genetic 
structure observed between Cape Coast and Navrongo 
parasite isolates through principal component analysis 
(Fig. 6b).
Evidence of selection within populations
Tajima’s D values were greater than zero in the TH2R 
and TH3R epitope regions of the C-terminal loci of Pfcsp 
(221,422–221,583) for the population of monoclonal 
Pfcsp isolates from Navrongo (Fig. 7a), suggesting balanc-
ing selection. However, a Tajima’s D < 0 was seen in the 
Cape Coast population at these loci, suggesting likely 
directional selection or clonal expansion in the popula-
tion. Alleles at SNP locus 221,554, which is within the 
segment encoding the TH2R epitope, had an |iHS|> 3 
in the Navrongo population, suggesting recent positive 
selection (Fig. 7c). The extended haplotype homozygosity 
revealed some extended haplotypes from the focal SNP 
Fig. 5 Plot a and b showing the percentage of isolates sharing specific amino acid haplotypes within the TH2R (311–327 aa) and TH3R (352–363 
aa) epitope regions in both Cape Coast and Navrongo population, respectively. Coloured columns in the bar graph represent the haplotypes. The 
proportion of samples in each population having the 3D7 haplotype (vaccine haplotype) is represented in the first purple‑coloured column from 
the bottom. The proportions of samples with non‑vaccine haplotypes are shown in the rest of the coloured column bars
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locus 221,554 in the Navrongo population, but no long-
range haplotypes extended beyond 221,554 (Fig. 8a, b).
Discussion
The RTS,S/AS01 malaria vaccine is based only on the 
Pfcsp sequence of the P. falciparum 3D7 clone [16], and 
strain-specific immunity has been confirmed for the 
licensed vaccine [15]. To provide new insights into how 
well RTS,S/AS01 may perform if administered on a large 
scale in different malaria-endemic regions, it is important 
to assess the intra-host diversity and extent of diversity in 
circulating parasites from different transmission settings.
Using Pfcsp sequence data generated from the whole-
genome sequencing of 92 and 128 clinical parasite 
isolates from Cape Coast in the coastal savanna region 
and the Kassena-Nankana districts (KNDs) in the 
Guinea savannah zone of the Upper East Region of 
Ghana, higher within-host malaria parasite diversity was 
observed in Navrongo, where 49.2% of infections exhib-
ited an Fws < 0.95, than in Cape Coast, where only 28.3% 
of infections exhibited an Fws < 0.95. This high genetic 
diversity is known to occur in high-transmission areas, 
where infected individuals usually harbour more poly-
clonal infections compared to those living in low-trans-
mission areas, where infections are often monoclonal 
[43]. Malaria transmission is much higher in Navrongo 
(EIR = 157) than in Cape Coast (EIR = 50) [20, 21]. These 
findings are consistent with high outcrossing potential 
Fig. 6 Population differentiation and structure. a Weir and Cockerham’s Fst calculated at SNP loci between Cape Coast (n = 92) and Navrongo 
(n = 128) population samples for 10 SNPs. The red line shows the borderline of 0.05 which indicates moderate population differentiation b. Plot 
of first (PC1) and second principal component (PC2) of samples in both the Cape Coast (n = 83) and Navrongo (n = 123) populations after outlier 
samples were removed
Fig. 7 a Tajima’s D plot in sliding windows of 100 and a step size of 10 of 66 mnoclonal Pfcsp samples (Cape Coast) and 65 monoclonal samples 
(Navrongo). The region highlighted in grey represents SNPs located in the C‑terminal region (221,422–221,583) of Pfcsp. Plots b and c show 
evidence of signatures of positive directional selection on chromosome 3 using the standardized integrated haplotype score (|iHS|) plotted as 
‑log10 (P value) (for 55 and 50 P. falciparum chromosome 3 monoclonal isolates) in both Cape Coast b and Navrongo c, respectively. IHS was 
calculated for SNPs with no missing data and a minor allele frequency > 0.05. SNPs on chromosome 3 are identified in red in Cape Coast b and blue 
in Navrongo c. Horizontal lines indicate the threshold for high‑scoring SNPs with a standardized |iHS|> 3. Vertical lines indicate the positions of Pfcsp 
in both Cape Coast and Navrongo, respectively. Evidence of positive directional selection was observed at Pfcsp loci in Navrongo; however, there 
was no evidence of selection in the Pfcsp loci from Cape Coast
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in the parasite population in the KNDs compared to the 
parasite population in the coastal town of Cape Coast. 
This marked difference in within-host diversity is note-
worthy for future region-specific vaccine intervention 
strategies.
High genetic diversity in the C-terminal TH2R and 
TH3R amino acid epitopes was observed at the two sites. 
Notably, the vaccine-specific Pf3D7-type haplotype in 
the TH2R and TH3R epitopes represented approximately 
56.5 and 79.3%, respectively, of the observed haplotypes 
in Cape Coast and only approximately 7.4 and 18.4% of 
those in the Navrongo isolates. The observed variance in 
location-specific diversity in these epitopes, which cor-
relates with malaria transmission intensity, is consistent 
with findings from previous studies [8–10, 44–46]. Such 
polymorphisms in T-cell epitopes have been suggested 
to be due to an immune evasion mechanism in response 
to host T-cell immune responses [10] or selection in the 
mosquito host during the malaria transmission cycle [44]. 
From 1 to 6 amino acid differences were observed within 
the TH2R and TH3R epitope regions at each epitope in 
both parasite populations, with implications for the dura-
tion of vaccine efficacy [13]. This situation is similar to 
the amino acid haplotype differences observed in the 
C-terminal region in the Zambian and DRC populations, 
ranging from 2 to 10 [16]. In addition, there were more 
amino acid substitutions in the Navrongo parasite popu-
lation than in the Cape Coast parasite population, which 
is consistent with the lower frequency of the vaccine hap-
lotype observed in the network analysis for the Navrongo 
parasite population, and this will have implications for 
vaccine efficacy in comparison with high-malaria-burden 
populations in Ghana. Another hypothesis drawn from a 
previous study suggests that polymorphism in the T cell 
epitopes could also be driven by an evolutionary response 
to intermolecular interactions at the surface of CSP [47].
The high degree of location-specific Pfcsp diversity 
observed in Ghana might result in differences in vac-
cine efficacy, potentially reducing RTS,S/AS01 vaccine 
effectiveness, particularly in Navrongo, where the vac-
cine haplotype was less prevalent. The monitoring of dif-
ferential vaccine efficacy according to Pfcsp haplotypes 
during RTS,S/AS01 implementation programmes will be 
valuable for such high-transmission areas, where post-
vaccination expansion of nonvaccine haplotypes in the 
population is likely to be observed, and this could lead 
to reduced vaccine efficacy and vaccine breakthrough 
infections.
The abundance of rare alleles shown in both Cape 
Coast and Navrongo contributes to the parasite popula-
tion. Despite this high level of genetic diversity result-
ing from nonsynonymous nucleotide and amino acid 
substitutions observed, a shared gene pool remained 
between the two sites that resulted in a largely homo-
geneous parasite population. Over the sampled range 
of 784.4 km between the two sites, there was gene flow 
between the local populations of P. falciparum according 
to Pfcsp sequence analysis, with a pairwise index of dif-
ferentiation (Fst) below 0.05. The principal component 
analysis further confirmed the lack of population struc-
ture or genetic isolation. Previous studies have indicated 
that human population mixing is likely to cause gene flow 
Fig. 8 Extended Haplotype Homozygosity (EHH) and Bifurcation diagram. a Plots of EHH showing extended haplotypes from a focal SNP locus 
(221,554). b Bifurcation diagrams showing the breakdown of these extended haplotypes from increasing distances in Navrongo parasite population. 
Evidence of positive directional selection was observed at this focal SNP locus, which is found in the TH2R epitope loci of Pfcsp 
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among P. falciparum parasites [48, 49]. Despite the eco-
logical and epidemiological diversity between the 2 sites, 
human movement between the two sites is significant 
and could account for Pfcsp gene flow within the country, 
with implications for the spread of any emerging vaccine-
resistant parasite. High levels of genetic recombination in 
the high-transmission area may explain the observed dif-
ferences in haplotype diversity in Navrongo in compari-
son with Cape Coast [50] despite the observed gene flow 
between the two sites.
The negative Tajima’s D observed in the Cape Coast 
isolates indicates a likely population expansion of the 
3D7 major haplotype in an area with moderate malaria 
transmission after over 15  years of enhanced nation-
wide malaria control interventions (chemotherapy and 
vector control). This result corroborates findings from 
Thiès, Senegal, where increased deployment of malaria 
control interventions resulted in an increase in the fre-
quency of clonal strains and a decrease in the probabil-
ity of multiple infections [51]. Evidence of recent positive 
and balancing selection was observed in the Navrongo 
parasite isolates. The majority of the alleles present in the 
C-terminal region in the Navrongo parasite population 
exhibited a positive Tajima’s D score and were highly pol-
ymorphic, likely due to balancing selection in response 
to host immune pressure on this immunogenic epitope 
[44, 52, 53]. Evidence of balancing selection on Pfcsp had 
been reported previously for a population from Malawi 
[44]. Balancing selection is common for immune targets 
and has been reported in other vaccine antigen candi-
dates, such as in the domain I epitope of the Pf38 gene 
(found on the merozoite surface) in Papua, New Guinea, 
and The Gambia [54] and in the extracellular domains 
of AMA1, a target of allele-specific immune responses 
[55]. However, seasonal genetic drift among loci attrib-
utable to sampling across multiple transmission sea-
sons in the Navrongo population may contribute to the 
observed balancing selection. The evidence of recent 
positive directional selection (iHS > 3) observed at the 
T-cell epitope loci in the Navrongo parasite population 
could be due to the addition of new and useful alleles to 
the already existing repertoire of alleles being maintained 
by balancing selection in the population [18]. However, 
the signature of positive selection observed in Navrongo 
could likely be attributed to the dominance of one allele 
over the others at the T-cell epitope region in the Nav-
rongo parasite population. Considering the differences 
in the eco-epidemiological background and the EIRs of 
these two populations, the intensity of transmission at 
these two ecologically distinct sites could account for dif-
ferences in selection signals observed [45].
The samples analysed here were nonrandomly selected 
from the population, and this lack of randomness may 
have some limitations and bias the inferences that can 
be drawn from Pfcsp and PfCSP diversity. Notably, the 
Navrongo and Cape Coast isolates were opportunistic 
samples whose sequence data were deposited into the 
Pf3K database at different times, leading to a geographi-
cally biased set of sequences, possibly over-representing 
limited genotypes from a small number of geographic 
foci and, in turn, under-representing large higher fre-
quency SNPs. Furthermore, the conclusions drawn from 
sequences obtained from any given sequence repository 
are subject to change as sample sizes and geographic 
and temporal distributions are continually updated and 
expanded. Another limitation that may affect the inter-
pretation of data is the small sample sizes analysed. 
Finally, the Navrongo sequences obtained from Pf3k 
come from different periods than the sequences from 
Cape Coast, which were sampled from the same periods. 
These limitations may prevent the samples from these 
two regions from being optimally comparable. There 
was, however, no population structure found within or 
between the two populations, indicating that the times-
pan did not affect the results obtained here. In addition, 
samples from Cape Coast were collected from a single 
district hospital, whereas the samples from Navrongo 
came from three health facilities. This circumstance 
may potentially have an impact on the results obtained, 
although the Cape Coast district hospital serves a wider 
catchment area, comparable to that of the three Nav-
rongo sites. Despite these inherent limitations, the 
sequence analysis elaborated here is a powerful approach 
capable of elucidating local patterns in vaccine candidate 
genetic diversity and would be useful for monitoring the 
effect and efficacy of interventions. The examination of a 
larger sample size allowing a geographically and tempo-
rally broader analysis will further reveal the extent of the 
diversity of Pfcsp both locally and across Africa. This will 
help inform strategies for a wider implementation of the 
RTS,S vaccine.
Conclusions
The extent of CSP polymorphism observed at the study 
sites likely indicates an allele-specific immune response 
during the pilot Phase IV implementation trials being 
conducted in Ghana. Similar to observations made in a 
study of an AMA-1 vaccine, vaccine efficacy during this 
trial in Ghana may be dependent on the degree of homol-
ogy between the amino acid haplotypes circulating in the 
natural parasite populations and the 3D7 vaccine haplo-
type [56]. This situation might gradually result in a direc-
tional selective advantage of unmatched CSP haplotypes 
because the vaccine does not target them, emphasizing 
the need for a polyvalent malaria vaccine [57, 58].
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With the ongoing Phase IV RTS,S vaccine implemen-
tation trials in Ghana, which include populations from 
Cape Coast and Navrongo, the findings from this study 
provide prior information on the extent of diversity in 
Pfcsp and the evolutionary forces driving these vari-
ations within Ghanaian natural parasite populations. 
These data will inform vaccine implementation out-
comes and contribute to future vaccine design. These 
findings further emphasize the need for incorporating 
large-scale prevalence and population genetic analysis 
of vaccine candidate antigens into future malaria vac-
cine design to predict malaria vaccine outcomes.
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